Role of ABC transporters in the chemoresistance of human gliomas

Current Cancer Drug Targets

Volumn 6, Issue 5, 2006, Pages 433-445

  Declèves, Xavier ^a,b,c,e   Amiel, Alexandra ^d   Delattre, Jean Yves ^d   Scherrmann, Jean Michel ^a,b,c  

^a HÔPITAL FERNAND WIDAL   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔTEL DIEU   (France)

Author keywords

ABC transporters; Astrocytes; Chemoresistance; Glioma

Indexed keywords

ABC TRANSPORTER; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; LOMUSTINE; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; NITROSOUREA; PACLITAXEL; PLATINUM DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; TOPOTECAN; VALSPODAR; VINBLASTINE; VINCRISTINE; ZOSUQUIDAR;

ASTROCYTE; BRAIN CANCER; CANCER GRADING; CANCER SURVIVAL; DRUG TRANSPORT; GLIA CELL; GLIOMA; HUMAN; MULTIDRUG RESISTANCE; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS;

EID: 33745845114     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906777723930     Document Type: Review

References (114)

1. Bredel, M. Anticancer drug resistance in primary human brain tumors. Brain Res. Brain Res. Rev. 2001, 35, 161-204.
2. Loscher, W.; Potschka, H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 2005, 76, 22-76.
3. Kemper, E. M.; Boogerd, W.; Thuis, I.; Beijnen, J. H.; van Tellingen, O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev. 2004, 30, 415-423.
4. Demeule, M.; Regina, A.; Jodoin, J.; Laplante, A.; Dagenais, C.; Berthelet, F.; Moghrabi, A.; Beliveau, R. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul. Pharmacol. 2002, 38, 339-348.
5. Graff, C. L.; Pollack, G. M. Drug transport at the blood-brain barrier and the choroid plexus. Curr. Drug Metab. 2004, 5, 95-108.
6. Spector, R.; Johanson, C. E. The mammalian choroid plexus. Sci. Am. 1989, 261, 68-74.
7. de Lange, E. C. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev. 2004, 56, 1793-1809.
8. Garcia-Garcia, E.; Andrieux, K.; Gil, S.; Couvreur, P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 2005, 298, 274-292.
9. Legler, J. M.; Ries, L. A.; Smith, M. A.; Warren, J. L.; Heineman, E. F.; Kaplan, R. S.; Linet, M. S. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl. Cancer Inst. 1999, 91, 1382-1390.
10. Louis, D. N.; Holland, E. C.; Cairncross, J. G. Glioma classification: a molecular reappraisal. Am. J. Pathol. 2001, 159, 779-786.
11. Okamoto, Y.; Di Patre, P. L.; Burkhard, C.; Horstmann, S.; Jourde, B.; Fahey, M.; Schuler, D.; Probst-Hensch, N. M.; Yasargil, M. G.; Yonekawa, Y.; Lutolf, U. M.; Kleihues, P.; Ohgaki, H. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. (Berl.) 2004, 108, 49-56.
12. Smits, A. Low-grade gliomas: clinical and pathobiological aspects. Histol. Histopathol. 2002, 17, 253-260.
13. Dropcho, E. J.; Soong, S. J. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology 1996, 47, 684-690.
14. Louis, D. N.; Pomeroy, S. L.; Cairncross, J. G. Focus on central nervous system neoplasia. Cancer Cell 2002, 1, 125-128.
15. Rasheed, B. K.; Wiltshire, R. N.; Bigner, S. H.; Bigner, D. D. Molecular pathogenesis of malignant gliomas. Curr. Opin. Oncol. 1999, 11, 162-167.
16. Tohma, Y.; Gratas, C.; Biernat, W.; Peraud, A.; Fukuda, M.; Yonekawa, Y.; Kleihues, P.; Ohgaki, H. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol. 1998, 57, 684-689.
17. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S. N.; Hidalgo, O. F.; Vanaclocha, V.; Baylin, S. B.; Herman, J. G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343, 1350-1354.
18. Hegi, M. E.; Diserens, A. C.; Godard, S.; Dietrich, P. Y.; Regli, L.; Ostermann, S.; Otten, P.; Van Melle, G.; de Tribolet, N.; Stupp, R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 2004, 10, 1871-1874.
19. Walker, M. D.; Alexander, E., Jr.; Hunt, W. E.; MacCarty, C. S.; Mahaley, M. S., Jr.; Mealey, J., Jr.; Norrell, H. A.; Owens, G.; Ransohoff, J.; Wilson, C. B.; Gehan, E. A.; Strike, T. A. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 1978, 49, 333-343.
20. Walker, M. D.; Green, S. B.; Byar, D. P.; Alexander, E., Jr.; Batzdorf, U.; Brooks, W. H.; Hunt, W. E.; MacCarty, C. S.; Mahaley, M. S., Jr.; Mealey, J., Jr.; Owens, G.; Ransohoff, J., 2nd; Robertson, J. T.; Shapiro, W. R.; Smith, K. R., Jr.; Wilson, C. B.; Strike, T. A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 1980, 303, 1323-1329.
21. Chang, C. H.; Horton, J.; Schoenfeld, D.; Salazer, O.; Perez-Tamayo, R.; Kramer, S.; Weinstein, A.; Nelson, J. S.; Tsukada, Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983, 52, 997-1007.
22. Stewart, L. A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359, 1011-1018.
23. Fine, H. A.; Dear, K. B.; Loeffler, J. S.; Black, P. M.; Canellos, G. P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71, 2585-2597.
24. Westphal, M.; Hilt, D. C.; Bortey, E.; Delavault, P.; Olivares, R.; Warnke, P. C.; Whittle, I. R.; Jaaskelainen, J.; Ram, Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. 2003, 5, 79-88.
25. Cairncross, J. G.; Macdonald, D. R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 1988, 23, 360-364.
26. Levin, V. A.; Edwards, M. S.; Wright, D. C.; Seager, M. L.; Schimberg, T. P.; Townsend, J. J.; Wilson, C. B. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat. Rep. 1980, 64, 237-244.
27. Glass, J.; Hochberg, F. H.; Gruber, M. L.; Louis, D. N.; Smith, D.; Rattner, B. The treatment of oligodendrogliomas and mixed oligodendroglioma- astrocytomas with PCV chemotherapy. J. Neurosurg. 1992, 76, 741-745.
28. Kyritsis, A. P.; Yung, W. K.; Bruner, J.; Gleason, M. J.; Levin, V. A. The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 1993, 32, 365-370; discussion 371.
29. Kristof, R. A.; Neuloh, G.; Hans, V.; Deckert, M.; Urbach, H.; Schlegel, U.; Simon, M.; Schramm, J. Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III. J. Neurooncol. 2002, 59, 231-237.
30. Kim, L.; Hochberg, F. H.; Thornton, A. F.; Harsh, G. R. t.; Patel, H.; Finkelstein, D.; Louis, D. N. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J. Neurosurg. 1996, 85, 602-607.
31. Cairncross, G.; Macdonald, D.; Ludwin, S.; Lee, D.; Cascino, T.; Buckner, J.; Fulton, D.; Dropcho, E.; Stewart, D.; Schold, C., Jr.; et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1994, 12, 2013-2021.
32. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
33. Chinot, O. L.; Honore, S.; Dufour, H.; Barrie, M.; Figarella-Branger, D.; Muracciole, X.; Braguer, D.; Martin, P. M.; Grisoli, F. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol. 2001, 19, 2449-2455.
34. Soffietti, R.; Nobile, M.; Ruda, R.; Borgognone, M.; Costanza, A.; Laguzzi, E.; Mutani, R. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Cancer 2004, 100, 807-813.
35. Brandes, A. A.; Basso, U.; Vastola, F.; Tosoni, A.; Pasetto, L. M.; Jirillo, A.; Lonardi, S.; Paris, M. K.; Koussis, H.; Monfardini, S.; Ermani, M. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Ann. Oncol. 2003, 14, 1727-1731.
36. Franceschi, E.; Cavallo, G.; Scopece, L.; Paioli, A.; Pession, A.; Magrini, E.; Conforti, R.; Palmerini, E.; Bartolini, S.; Rimondini, S.; Esposti, R. D.; Crino, L. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br. J. Cancer 2004, 91, 1038-1044.
37. Wolff, J. E.; Trilling, T.; Molenkamp, G.; Egeler, R. M.; Jurgens, H. Chemosensitivity of glioma cells in vitro: a meta analysis. J. Cancer Res. Clin. Oncol. 1999, 125, 481-486.
38. Hau, P.; Fabel, K.; Baumgart, U.; Rummele, P.; Grauer, O.; Bock, A.; Dietmaier, C.; Dietmaier, W.; Dietrich, J.; Dudel, C.; Hubner, F.; Jauch, T.; Drechsel, E.; Kleiter, I.; Wismeth, C.; Zellner, A.; Brawanski, A.; Steinbrecher, A.; Marienhagen, J.; Bogdahn, U. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004, 100, 1199-1207.
39. Fabel, K.; Dietrich, J.; Hau, P.; Wismeth, C.; Winner, B.; Przywara, S.; Steinbrecher, A.; Ullrich, W.; Bogdahn, U. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001, 92, 1936-1942.
40. Voulgaris, S.; Partheni, M.; Karamouzis, M.; Dimopoulos, P.; Papadakis, N.; Kalofonos, H. P. Intratumoral doxorubicin in patients with malignant brain gliomas. Am. J. Clin. Oncol. 2002, 25, 60-64.
41. Friedman, H. S.; Petros, W. P.; Friedman, A. H.; Schaaf, L. J.; Kerby, T.; Lawyer, J.; Parry, M.; Houghton, P. J.; Lovell, S.; Rasheed, K.; Cloughsey, T.; Stewart, E. S.; Colvin, O. M.; Provenzale, J. M.; McLendon, R. E.; Bigner, D. D.; Cokgor, I.; Haglund, M.; Rich, J.; Ashley, D.; Malczyn, J.; Elfring, G. L.; Miller, L. L. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 1999, 17, 1516-1525.
42. Bart, J.; Groen, H. J.; Hendrikse, N. H.; van der Graaf, W. T.; Vaalburg, W.; de Vries, E. G. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat. Rev. 2000, 26, 449-462.
43. Hagenbuch, B.; Gao, B.; Meier, P. J. Transport of xenobiotics across the blood-brain barrier. News Physiol. Sci. 2002, 17, 231-234.
44. Lee, G.; Dallas, S.; Hong, M.; Bendayan, R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 2001, 53, 569-596.
45. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
46. Leslie, E. M.; Deeley, R. G.; Cole, S. P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204, 216-237.
47. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455, 152-162.
48. Cordon-Cardo, C.; O'Brien, J. P.; Casals, D.; Rittman-Grauer, L.; Biedler, J. L.; Melamed, M. R.; Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 1989, 86, 695-698.
49. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J . Histochem. Cytochem. 1989, 37, 159-164.
50. Golden, P. L.; Pardridge, W. M. P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res. 1999, 819, 143-146.
51. Pardridge, W. M.; Golden, P. L.; Kang, Y. S.; Bickel, U. Brain microvascular and astrocyte localization of P-glycoprotein. J. Neurochem. 1997, 68, 1278-1285.
52. Decleves, X.; Regina, A.; Laplanche, J. L.; Roux, F.; Boval, B.; Launay, J. M.; Scherrmann, J. M. Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J. Neurosci. Res. 2000, 60, 594-601.
53. Monville, C.; Fages, C.; Feyens, A. M.; D'Hondt, V.; Guillet, C.; Vernallis, A.; Gascan, H.; Peschanski, M. Astroglial expression of the P-glycoprotein is controlled by intracellular CNTF. BMC Cell Biol. 2002, 3, 20.
54. Ronaldson, P. T.; Bendayan, M.; Gingras, D.; Piquette-Miller, M.; Bendayan, R. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J. Neurochem. 2004, 89, 788-800.
55. Jodoin, J.; Demeule, M.; Fenart, L.; Cecchelli, R.; Farmer, S.; Linton, K. J.; Higgins, C. F.; Beliveau, R. P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J. Neurochem. 2003, 87, 1010-1023.
56. Mercier, C.; Decleves, X.; Masseguin, C.; Fragner, P.; Tardy, M.; Roux, F.; Gabrion, J.; Scherrmann, J. M. P-glycoprotein (ABCB1) but not multidrug resistance-associated protein 1 (ABCC1) is induced by doxorubicin in primary cultures of rat astrocytes. J. Neurochem. 2003, 87, 820-830.
57. Fardel, O.; Lecureur, V.; Daval, S.; Corlu, A.; Guillouzo, A. Upregulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur. J. Biochem. 1997, 246, 186-192.
58. Regina, A.; Koman, A.; Piciotti, M.; El Hafny, B.; Center, M. S.; Bergmann, R.; Couraud, P. O.; Roux, F. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 1998, 71, 705-715.
59. Kwan, P.; Sills, G. J.; Butler, E.; Gant, T. W.; Brodie, M. J. Differential expression of multidrug resistance genes in naive rat brain. Neurosci. Lett. 2003, 339, 33-36.
60. Aronica, E.; Gorter, J. A.; Ramkema, M.; Redeker, S.; Ozbas-Gerceker, F.; van Vliet, E. A.; Scheffer, G. L.; Scheper, R. J.; van der Valk, P.; Baayen, J. C.Troost, D. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004, 45, 441-451.
61. Mercier, C.; Masseguin, C.; Roux, F.; Gabrion, J.; Scherrmann, J. M. Expression of P-glycoprotein (ABCB1) and Mrp1 (ABCC1) in adult rat brain: focus on astrocytes. Brain Res. 2004, 1021, 32-40.
62. Tishler, D. M.; Weinberg, K. I.; Hinton, D. R.; Barbaro, N.; Annett, G. M.Raffel, C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36, 1-6.
63. Marroni, M.; Agrawal, M. L.; Kight, K.; Hallene, K. L.; Hossain, M.; Cucullo, L.; Signorelli, K.; Namura, S.; Bingaman, W.; Janigro, D. Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes. Neuroscience 2003, 121, 605-17.
64. Spiegl-Kreinecker, S.; Buchroithner, J.; Elbling, L.; Steiner, E.; Wurm, G.; Bodenteich, A.; Fischer, J.; Micksche, M.; Berger, W. Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J. Neurooncol. 2002, 57, 27-36.
65. Aronica, E.; Gorter, J. A.; Jansen, G. H.; van Veelen, C. W.; van Rijen, P. C.; Leenstra, S.; Ramkema, M.; Scheffer, G. L.; Scheper, R. J.; Troost, D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003, 118, 417-429.
66. Langford, D.; Grigorian, A.; Hurford, R.; Adame, A.; Ellis, R. J.; Hansen, L.; Masliah, E. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J. Neuropathol. Exp. Neurol. 2004, 63, 1038-1047.
67. Ashmore, S. M.; Thomas, D. G.; Darling, J. L. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? Anticancer Drugs 1999, 10, 861-872.
68. Decleves, X.; Fajac, A.; Lehmann-Che, J.; Tardy, M.; Mercier, C.; Hurbain, I.; Laplanche, J. L.; Bernaudin, J. F.; Scherrmann, J. M. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int. J. Cancer 2002, 98, 173-180.
69. Matsumoto, T.; Tani, E.; Kaba, K.; Shindo, H.; Miyaji, K. Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J. Neurosurg. 1991, 74, 460-466.
70. Kirches, E.; Oda, Y.; Von Bossanyi, P.; Diete, S.; Schneider, T.; Warich-Kirches, M.; Dietzmann, K. Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas. Clin. Neuropathol. 1997, 16, 34-36.
71. Henson, J. W.; Cordon-Cardo, C.; Posner, J. B. P-glycoprotein expression in brain tumors. J. Neurooncol. 1992, 14, 37-43.
72. Abe, T.; Mori, T.; Wakabayashi, Y.; Nakagawa, M.; Cole, S. P.; Koike, K.; Kuwano, M.; Hori, S. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J. Neurooncol. 1998, 40, 11-18.
73. Tews, D. S.; Nissen, A.; Kulgen, C.; Gaumann, A. K. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J. Neurooncol. 2000, 50, 227-237.
74. Bahr, O.; Rieger, J.; Duffner, F.; Meyermann, R.; Weller, M.; Wick, W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol. 2003, 13, 482-494.
75. Nagane, M.; Asai, A.; Shibui, S.; Oyama, H.; Nomura, K.; Kuchino, Y. Expression pattern of chemoresistance-related genes in human malignant brain tumors: a working knowledge for proper selection of anticancer drugs. Jpn J. Clin. Oncol. 1999, 29, 527-534.
76. Abe, T.; Hasegawa, S.; Taniguchi, K.; Yokomizo, A.; Kuwano, T.; Ono, M.; Mori, T.; Hori, S.; Kohno, K.; Kuwano, M. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int. J. Cancer 1994, 58, 860-864.
77. Abe, T.; Koike, K.; Ohga, T.; Kubo, T.; Wada, M.; Kohno, K.; Mori, T.; Hidaka, K.; Kuwano, M. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br. J. Cancer 1995, 72, 418-423.
78. Reavey-Cantwell, J. F.; Haroun, R. I.; Zahurak, M.; Clatterbuck, R. E.; Parker, R. J.; Mehta, R.; Fruehauf, J. P.; Brem, H. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J. Neurooncol. 2001, 55, 195-204.
79. Andersson, U.; Malmer, B.; Bergenheim, A. T.; Brannstrom, T.; Henriksson, R. Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin. Neuropathol. 2004, 23, 21-27.
80. Rieger, L.; Rieger, J.; Winter, S.; Streffer, J.; Esser, P.; Dichgans, J.; Meyermann, R.; Weller, M. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo. Acta. Neuropathol. (Berl.) 2000, 99, 555-562.
81. Calatozzolo, C.; Gelati, M.; Ciusani, E.; Sciacca, F. L.; Pollo, B.; Cajola, L.; Marras, C.; Silvani, A.; Vitellaro-Zuccarello, L.; Croci, D.; Boiardi, A.; Salmaggi, A. Expression of Drug Resistance Proteins Pgp, MRP1, MRP3, MRP5 AND GST-pi in Human Glioma. J. Neurooncol. 2005, 74, 113-121.
82. Breedveld, P.; Pluim, D.; Cipriani, G.; Wielinga, P.; van Tellingen, O.; Schinkel, A. H.; Schellens, J. H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005, 65, 2577-2582.
83. Holdhoff, M.; Kreuzer, K. A.; Appelt, C.; Scholz, R.; Na, I. K.; Hildebrandt, B.; Riess, H.; Jordan, A.; Schmidt, C. A.; Van Etten, R. A.; Dorken, B.; le Coutre, P. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol. Dis. 2005, 34, 181-185.
84. O'Reilly, T.; Wartmann, M.; Maira, S. M.; Hattenberger, M.; Vaxelaire, J.; Muller, M.; Ferretti, S.; Buchdunger, E.; Altmann, K. H.; McSheehy, P. M. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother. Pharmacol. 2005, 55, 307-317.
85. Boruban, C.; Yavas, O.; Altundag, O.; Altundag, M. B.Altundag, K. Imatinib may be useful in the management of patients with glioblastoma. Med. Hypotheses 2005, 65, 1205-1206.
86. Hirrlinger, J.; Konig, J.; Keppler, D.; Lindenau, J.; Schulz, J. B.; Dringen, R. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J. Neurochem. 2001, 76, 627-636.
87. Hirrlinger, J.; Konig, J.; Dringen, R. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J. Neurochem. 2002, 82, 716-719.
88. Gennuso, F.; Fernetti, C.; Tirolo, C.; Testa, N.; L'Episcopo, F.; Caniglia, S.; Morale, M. C.; Ostrow, J. D.; Pascolo, L.; Tiribelli, C.; Marchetti, B. Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc. Natl. Acad. Sci. USA 2004, 101, 2470-2475.
89. Nies, A. T.; Jedlitschky, G.; Konig, J.; Herold-Mende, C.; Steiner, H. H.; Schmitt, H. P.; Keppler, D. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004, 129, 349-360.
90. Mohri, M.; Nitta, H.; Yamashita, J. Expression of multidrug resistance-associated protein (MRP) in human gliomas. J . Neurooncol. 2000, 49, 105-115.
91. Benyahia, B.; Huguet, S.; Decleves, X.; Mokhtari, K.; Criniere, E.; Bernaudin, J. F.; Scherrmann, J. M.; Delattre, J. Y. Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J. Neurooncol. 2004, 66, 65-70.
92. Potschka, H.; Fedrowitz, M.; Loscher, W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther. 2003, 306, 124-131.
93. Matsumoto, Y.; Tamiya, T.; Nagao, S. Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2. J. Med. Invest. 2005, 52, 41-48.
94. Haga, S.; Hinoshita, E.; Ikezaki, K.; Fukui, M.; Scheffer, G. L.; Uchiumi, T.; Kuwano, M. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J. Cancer Res. 2001, 92, 211-219.
95. Young, L. C.; Campling, B. G.; Voskoglou-Nomikos, T.; Cole, S. P.; Deeley, R. G.; Gerlach, J. H. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res. 1999, 5, 673-680.
96. Zeng, H.; Bain, L. J.; Belinsky, M. G.; Kruh, G. D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 1999, 59, 5964-5967.
97. Zelcer, N.; van de Wetering, K.; Hillebrand, M.; Sarton, E.; Kuil, A.; Wielinga, P. R.; Tephly, T.; Dahan, A.; Beijnen, J. H.; Borst, P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl. Acad. Sci. USA 2005, 102, 7274-7279.
98. Leggas, M.; Adachi, M.; Scheffer, G. L.; Sun, D.; Wielinga, P.; Du, G.; Mercer, K. E.; Zhuang, Y.; Panetta, J. C.; Johnston, B.; Scheper, R. J.; Stewart, C. F.; Schuetz, J. D. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell Biol. 2004, 24, 7612-7621.
99. Chen, C.; Klaassen, C. D. Rat multidrug resistance protein 4 (Mrp4, Abcc4): molecular cloning, organ distribution, postnatal renal expression, and chemical inducibility. Biochem. Biophys. Res. Comm. 2004, 317, 46-53.
100. Ballerini, P.; Di Iorio, P.; Ciccarelli, R.; Nargi, E.; D'Alimonte, I.; Traversa, U.; Rathbone, M. P.; Caciagli, F. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. Neuroreport 2002, 13, 1789-1792.
101. Dallas, S.; Schlichter, L.; Bendayan, R. Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia. J. Pharmacol. Exp. Ther. 2004, 309, 1221-1229.
102. Berezowski, V.; Landry, C.; Dehouck, M. P.; Cecchelli, R.; Fenart, L. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res. 2004, 1018, 1-9.
103. Savaraj, N.; Wu, C.; Wangpaichitr, M.; Kuo, M. T.; Lampidis, T.; Robles, C.; Furst, A. J.; Feun, L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int. J. Oncol. 2003, 23, 173-179.
104. Zhang, Y.; Han, H.; Elmquist, W. F.; Miller, D. W. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 2000, 876, 148-153.
105. Kool, M.; de Haas, M.; Scheffer, G. L.; Scheper, R. J.; van Eijk, M. J.; Juijn, J. A.; Baas, F.; Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57, 3537-3547.
106. Oguri, T.; Isobe, T.; Suzuki, T.; Nishio, K.; Fujiwara, Y.; Katoh, O.; Yamakido, M. Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int. J. Cancer 2000, 86, 95-100.
107. Beck, K.; Hayashi, K.; Dang, K.; Hayashi, M.; Boyd, C. D. Analysis of ABCC6 (MRP6) in normal human tissues. Histochem. Cell Biol. 2005, 123, 517-528.
108. Eisenblatter, T.; Galla, H. J. A new multidrug resistance protein at the blood-brain barrier. Biochem. Biophys. Res. Comm. 2002, 293, 1273-1278.
109. Cooray, H. C.; Blackmore, C. G.; Maskell, L.; Barrand, M. A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002, 13, 2059-2063.
110. Zhang, W.; Mojsilovic-Petrovic, J.; Andrade, M. F.; Zhang, H.; Ball, M.; Stanimirovic, D. B. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J. 2003, 17, 2085-2087.
111. Aronica, E.; Gorter, J. A.; Redeker, S.; van Vliet, E. A.; Ramkema, M.; Scheffer, G. L.; Scheper, R. J.; van der Valk, P.; Leenstra, S.; Baayen, J. C.; Spliet, W. G.; Troost, D. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005, 46, 849-857.
112. Wijnholds, J.; deLange, E. C.; Scheffer, G. L.; van den Berg, D. J.; Mol, C. A.; van der Valk, M.; Schinkel, A. H.; Scheper, R. J.; Breimer, D. D.; Borst, P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 2000, 105, 279-285.
113. Athanassiou, H.; Synodinou, M.; Maragoudakis, E.; Paraskevaidis, M.; Verigos, C.; Misailidou, D.; Antonadou, D.; Saris, G.; Beroukas, K.; Karageorgis, P. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 2005, 23, 2372-2377.
114. Chan, L. M.; Lowes, S.; Hirst, B. H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 2004, 21, 25-51